Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin
Authors:
Open Access
- 9 October 2009
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 116 (12) , 1585-1592
Abstract
Objective To determine maternal and fetal outcomes in women with mechanical heart valves managed with therapeutic dose enoxaparin during pregnancy.Design Retrospective audit.Setting Hospital‐based high‐risk antenatal clinics.Population Pregnant women with mechanical heart valves attending high‐risk antenatal clinics, treated with enoxaparin (1 mg/kg twice daily) during pregnancy.Methods Women with mechanical heart valves treated with enoxaparin at any stage during pregnancy (1997–2008) identified using a database of women with mechanical heart valves attending the high‐risk clinics and a prospective database of women prescribed enoxaparin for any indication during pregnancy.Main outcome measures Maternal outcomes included thromboembolic and haemorrhagic complications. Pregnancy and fetal outcomes included miscarriage, stillbirth, baby death and live birth, small‐for‐gestational‐age infants, warfarin embryopathy and warfarin‐related fetal loss.Results Thirty‐one women underwent 47 pregnancies. In 34 pregnancies (72.3%), anticoagulation was with predominantly enoxaparin and 13 (27.7%) pregnancies women received mainly warfarin, with enoxaparin given in the first trimester and/or peri‐delivery. Seven (14.9%) thrombotic complications occurred, of which five (10.6%) were associated with enoxaparin treatment. Non‐compliance or sub‐therapeutic anti‐Xa levels contributed in each case. Antenatal and postpartum haemorrhagic complications occurred in eight (17%) and 15 (32%) pregnancies respectively. Of 35 pregnancies continuing after 20 weeks’ gestation, 96% (22/23) of women taking predominantly enoxaparin had a surviving infant compared with 75% (9/12) in women taking primarily warfarin. Four perinatal deaths occurred, three attributable to warfarin.Conclusions Compliance with therapeutic dose enoxaparin and aspirin during pregnancy in women with mechanical heart valves is associated with a low risk of valve thrombosis and good fetal outcomes, but close monitoring is essential.Keywords
This publication has 15 references indexed in Scilit:
- Management of pregnant women with mechanical heart valve prosthesis: Thromboprophylaxis with Low molecular weight heparinThrombosis Research, 2009
- 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart DiseaseJACC, 2008
- Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valvesThe Journal of Maternal-Fetal & Neonatal Medicine, 2006
- Valvular Heart Disease and PregnancyJACC, 2005
- Customised birthweight centiles predict SGA pregnancies with perinatal morbidityBJOG: An International Journal of Obstetrics & Gynaecology, 2005
- Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancyThrombosis and Haemostasis, 2004
- Teratogen update: Fetal effects after in utero exposure to coumarins Overview of cases, follow‐up findings, and pathogenesisTeratology, 2002
- Risk of warfarin during pregnancy with mechanical valve prosthesesObstetrics & Gynecology, 2002
- A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve ReplacementNew England Journal of Medicine, 1993
- Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight HeparinsDrugs, 1990